Cargando…
COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil
The accuracy of commercially available tests for COVID-19 in Brazil remains unclear. We aimed to perform a meta-analysis to describe the accuracy of available tests to detect COVID-19 in Brazil. We searched at the Brazilian Health Regulatory Agency (ANVISA) online platform to describe the pooled sen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165277/ https://www.ncbi.nlm.nih.gov/pubmed/32330437 http://dx.doi.org/10.1016/j.bjid.2020.04.003 |
_version_ | 1783523442182586368 |
---|---|
author | Castro, Rodolfo Luz, Paula M. Wakimoto, Mayumi D. Veloso, Valdilea G. Grinsztejn, Beatriz Perazzo, Hugo |
author_facet | Castro, Rodolfo Luz, Paula M. Wakimoto, Mayumi D. Veloso, Valdilea G. Grinsztejn, Beatriz Perazzo, Hugo |
author_sort | Castro, Rodolfo |
collection | PubMed |
description | The accuracy of commercially available tests for COVID-19 in Brazil remains unclear. We aimed to perform a meta-analysis to describe the accuracy of available tests to detect COVID-19 in Brazil. We searched at the Brazilian Health Regulatory Agency (ANVISA) online platform to describe the pooled sensitivity (Se), specificity (Sp), diagnostic odds ratio (DOR) and summary receiver operating characteristic curves (SROC) for detection of IgM/IgG antibodies and for tests using naso/oropharyngeal swabs in the random-effects models. We identified 16 tests registered, mostly rapid-tests. Pooled diagnostic accuracy measures [95%CI] were: (i) for IgM antibodies Se = 82% [76–87]; Sp = 97% [96–98]; DOR = 168 [92–305] and SROC = 0.98 [0.96–0.99]; (ii) for IgG antibodies Se = 97% [90–99]; Sp = 98% [97–99]; DOR = 1994 [385–10334] and SROC = 0.99 [0.98–1.00]; and (iii) for detection of SARS-CoV-2 by antigen or molecular assays in naso/oropharyngeal swabs Se = 97% [85–99]; Sp = 99% [77–100]; DOR = 2649 [30–233056] and SROC = 0.99 [0.98–1.00]. These tests can be helpful for emergency testing during the COVID-19 pandemic in Brazil. However, it is important to highlight the high rate of false negative results from tests which detect SARS-CoV-2 IgM antibodies in the initial course of the disease and the scarce evidence-based validation results published in Brazil. Future studies addressing the diagnostic performance of tests for COVID-19 in the Brazilian population are urgently needed. |
format | Online Article Text |
id | pubmed-7165277 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-71652772020-04-20 COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil Castro, Rodolfo Luz, Paula M. Wakimoto, Mayumi D. Veloso, Valdilea G. Grinsztejn, Beatriz Perazzo, Hugo Braz J Infect Dis Brief Communication The accuracy of commercially available tests for COVID-19 in Brazil remains unclear. We aimed to perform a meta-analysis to describe the accuracy of available tests to detect COVID-19 in Brazil. We searched at the Brazilian Health Regulatory Agency (ANVISA) online platform to describe the pooled sensitivity (Se), specificity (Sp), diagnostic odds ratio (DOR) and summary receiver operating characteristic curves (SROC) for detection of IgM/IgG antibodies and for tests using naso/oropharyngeal swabs in the random-effects models. We identified 16 tests registered, mostly rapid-tests. Pooled diagnostic accuracy measures [95%CI] were: (i) for IgM antibodies Se = 82% [76–87]; Sp = 97% [96–98]; DOR = 168 [92–305] and SROC = 0.98 [0.96–0.99]; (ii) for IgG antibodies Se = 97% [90–99]; Sp = 98% [97–99]; DOR = 1994 [385–10334] and SROC = 0.99 [0.98–1.00]; and (iii) for detection of SARS-CoV-2 by antigen or molecular assays in naso/oropharyngeal swabs Se = 97% [85–99]; Sp = 99% [77–100]; DOR = 2649 [30–233056] and SROC = 0.99 [0.98–1.00]. These tests can be helpful for emergency testing during the COVID-19 pandemic in Brazil. However, it is important to highlight the high rate of false negative results from tests which detect SARS-CoV-2 IgM antibodies in the initial course of the disease and the scarce evidence-based validation results published in Brazil. Future studies addressing the diagnostic performance of tests for COVID-19 in the Brazilian population are urgently needed. Elsevier 2020-04-18 /pmc/articles/PMC7165277/ /pubmed/32330437 http://dx.doi.org/10.1016/j.bjid.2020.04.003 Text en © 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Brief Communication Castro, Rodolfo Luz, Paula M. Wakimoto, Mayumi D. Veloso, Valdilea G. Grinsztejn, Beatriz Perazzo, Hugo COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil |
title | COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil |
title_full | COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil |
title_fullStr | COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil |
title_full_unstemmed | COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil |
title_short | COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil |
title_sort | covid-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in brazil |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165277/ https://www.ncbi.nlm.nih.gov/pubmed/32330437 http://dx.doi.org/10.1016/j.bjid.2020.04.003 |
work_keys_str_mv | AT castrorodolfo covid19ametaanalysisofdiagnostictestaccuracyofcommercialassaysregisteredinbrazil AT luzpaulam covid19ametaanalysisofdiagnostictestaccuracyofcommercialassaysregisteredinbrazil AT wakimotomayumid covid19ametaanalysisofdiagnostictestaccuracyofcommercialassaysregisteredinbrazil AT velosovaldileag covid19ametaanalysisofdiagnostictestaccuracyofcommercialassaysregisteredinbrazil AT grinsztejnbeatriz covid19ametaanalysisofdiagnostictestaccuracyofcommercialassaysregisteredinbrazil AT perazzohugo covid19ametaanalysisofdiagnostictestaccuracyofcommercialassaysregisteredinbrazil |